

Lanying Du

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/457046/lanying-du-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101
papers

9,892
citations

52
h-index

99
g-index

110
ext. papers

12,170
ext. citations

8.8
avg, IF

7.13
L-index

#	Paper	IF	Citations
101	Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant.. <i>Cellular and Molecular Immunology</i> , 2022 ,	15.4	5
100	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies.. <i>Nanoscale</i> , 2022 ,	7.7	5
99	Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. <i>Biophysical Journal</i> , 2021 , 120, 1011-1019	2.9	26
98	A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage. <i>Cell Reports</i> , 2021 , 35, 109107	10.6	5
97	Learning from the past: development of safe and effective COVID-19 vaccines. <i>Nature Reviews Microbiology</i> , 2021 , 19, 211-219	22.2	75
96	SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 95	21	39
95	The development of - as anti-SARS-CoV-2 nanobody drug candidates. <i>ELife</i> , 2021 , 10,	8.9	10
94	Neutralizing antibodies for the prevention and treatment of COVID-19. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 2293-2306	15.4	21
93	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2021 , 17, e1009897	7.6	11
92	Neutralizing antibodies for the treatment of COVID-19. <i>Nature Biomedical Engineering</i> , 2020 , 4, 1134-1139	19	52
91	Current development of COVID-19 diagnostics, vaccines and therapeutics. <i>Microbes and Infection</i> , 2020 , 22, 231-235	9.3	34
90	From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. <i>Microbes and Infection</i> , 2020 , 22, 245-253	9.3	28
89	Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. <i>Antiviral Research</i> , 2020 , 179, 104820	10.8	71
88	Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 613-620	15.4	910
87	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. <i>Cell Research</i> , 2020 , 30, 343-355	24.7	745
86	The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. <i>Vaccines</i> , 2020 , 8,	5.3	6
85	Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. <i>Frontiers in Microbiology</i> , 2020 , 11, 298	5.7	188

84	Recent advances in the detection of respiratory virus infection in humans. <i>Journal of Medical Virology</i> , 2020 , 92, 408-417	19.7	233
83	Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. <i>Microbes and Infection</i> , 2020 , 22, 74-79	9.3	220
82	Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. <i>Journal of Virology</i> , 2020 , 94,	6.6	402
81	Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. <i>Trends in Immunology</i> , 2020 , 41, 355-359	14.4	476
80	Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. <i>Trends in Immunology</i> , 2020 , 41, 853-854	14.4	8
79	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. <i>Emerging Microbes and Infections</i> , 2020 , 9, 275-277	18.9	210
78	Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement 2020 ,		23
77	Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction 2020 ,		6
76	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. <i>Vaccine</i> , 2020 , 38, 7533-7541	4.1	50
75	A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. <i>Cell Research</i> , 2020 , 30, 932-935	24.7	73
74	Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines. <i>Vaccines</i> , 2020 , 8,	5.3	7
73	An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies. <i>Expert Review of Vaccines</i> , 2020 , 19, 817-829	5.2	2
72	Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy. <i>Journal of Virology</i> , 2019 , 93,	6.6	21
71	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. <i>Molecules</i> , 2019 , 24,	4.8	14
70	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. <i>Science Advances</i> , 2019 , 5, eaav4580	14.3	268
69	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. <i>Frontiers in Microbiology</i> , 2019 , 10, 29	5.7	10
68	Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain. <i>Viruses</i> , 2019 , 11,	6.2	16
67	Advances in the research and development of therapeutic antibodies against the Zika virus. <i>Cellular and Molecular Immunology</i> , 2019 , 16, 96-97	15.4	9

66	Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors. <i>Viruses</i> , 2019 , 11,	6.2	26
65	Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine. <i>Vaccines</i> , 2019 , 7,	5.3	6
64	Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. <i>Viruses</i> , 2019 , 11,	6.2	69
63	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. <i>Vaccine</i> , 2018 , 36, 1853-1862	4.1	44
62	Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. <i>Emerging Microbes and Infections</i> , 2018 , 7, 7	18.9	30
61	Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application. <i>Critical Care Medicine</i> , 2018 , 46, e419-e425	1.4	14
60	A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. <i>Journal of Virology</i> , 2018 , 92,	6.6	62
59	Prospects for a MERS-CoV spike vaccine. <i>Expert Review of Vaccines</i> , 2018 , 17, 677-686	5.2	83
58	Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2017 , 13, 1615-1624	4.4	43
57	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. <i>Journal of Infection</i> , 2017 , 75, 68-71	18.9	6
56	MERS-CoV spike protein: a key target for antivirals. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 131-143	4.3	176
55	Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. <i>Microbes and Infection</i> , 2017 , 19, 641-647	9.3	12
54	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. <i>Nature Communications</i> , 2017 , 8, 15672	17.4	83
53	Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. <i>Science China Life Sciences</i> , 2017 , 60, 1399-1402	8.5	23
52	Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. <i>Journal of Virology</i> , 2017 , 91,	6.6	58
51	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. <i>Emerging Microbes and Infections</i> , 2017 , 6, e89	18.9	33
50	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. <i>Journal of Virology</i> , 2016 , 90, 57-67	6.6	64
49	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. <i>Nature Communications</i> , 2016 , 7, 13473	17.4	77

48	A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. <i>Virology</i> , 2016 , 499, 375-382	3.6	76
47	Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. <i>Antiviral Research</i> , 2016 , 132, 141-8	10.8	43
46	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. <i>Cellular and Molecular Immunology</i> , 2016 , 13, 180-90	15.4	96
45	Vaccines for the prevention against the threat of MERS-CoV. <i>Expert Review of Vaccines</i> , 2016 , 15, 1123-34.2	3.2	64
44	Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. <i>Human Vaccines and Immunotherapeutics</i> , 2015 , 11, 1244-50	4.4	60
43	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1894-903	7.03	71
42	Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. <i>Journal of Virology</i> , 2015 , 89, 6121-5	6.6	129
41	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. <i>Lancet, The</i> , 2015 , 386, S44	4.0	3
40	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. <i>Nature Communications</i> , 2015 , 6, 8223	17.4	90
39	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. <i>Scientific Reports</i> , 2015 , 5, 13028	4.9	25
38	Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. <i>Journal of Virology</i> , 2015 , 89, 9119-23	6.6	96
37	Receptor-binding domain-based subunit vaccines against MERS-CoV. <i>Virus Research</i> , 2015 , 202, 151-9	6.4	49
36	Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. <i>PLoS ONE</i> , 2015 , 10, e0145561	3.7	59
35	Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin. <i>Oncotarget</i> , 2015 , 6, 29196-208 ³ .3	3.3	3
34	A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. <i>Journal of Virology</i> , 2014 , 88, 7045-53	6.6	112
33	Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. <i>Journal of Virology</i> , 2014 , 88, 7796-805	6.6	182
32	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. <i>Nature Communications</i> , 2014 , 5, 3067	17.4	247
31	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. <i>Virus Research</i> , 2014 , 194, 200-10	6.4	79

30	Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. <i>Vaccine</i> , 2014 , 32, 6170-6176	4.1	102
29	Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 12516-21	11.5	182
28	Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. <i>Vaccine</i> , 2014 , 32, 2100-8	4.1	107
27	Current advancements and potential strategies in the development of MERS-CoV vaccines. <i>Expert Review of Vaccines</i> , 2014 , 13, 761-74	5.2	113
26	Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. <i>Human Vaccines and Immunotherapeutics</i> , 2014 , 10, 648-58	4.4	82
25	Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1 α . <i>Nucleic Acids Research</i> , 2014 , 42, 6578-90	20.1	60
24	A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. <i>Virology Journal</i> , 2013 , 10, 266	6.1	102
23	Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. <i>Journal of Virology</i> , 2013 , 87, 9939-42	6.6	140
22	A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. <i>PLoS ONE</i> , 2013 , 8, e53568	3.7	24
21	A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. <i>PLoS ONE</i> , 2013 , 8, e81587	3.7	126
20	A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses. <i>BioScience Trends</i> , 2013 , 7, 129-37	9.9	11
19	A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. <i>Viral Immunology</i> , 2010 , 23, 211-9	1.7	40
18	An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. <i>Virology Journal</i> , 2010 , 7, 151	6.1	30
17	Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. <i>Virology Journal</i> , 2010 , 7, 299	6.1	52
16	An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. <i>Virology Journal</i> , 2010 , 7, 9	6.1	72
15	Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 397, 580-5	3.4	28
14	Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. <i>Vaccine</i> , 2010 , 28, 7233-40	4.1	28
13	Research and development of universal influenza vaccines. <i>Microbes and Infection</i> , 2010 , 12, 280-6	9.3	88

12	Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. <i>Virology</i> , 2009 , 393, 144-50 ^{3.6}	93
11	The spike protein of SARS-CoV--a target for vaccine and therapeutic development. <i>Nature Reviews Microbiology</i> , 2009 , 7, 226-36	22.2 1007
10	Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. <i>Vaccine</i> , 2008 , 26, 1644-51	4.1 67
9	Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. <i>Journal of Immunology</i> , 2008 , 180, 948-56	5.3 102
8	Development of subunit vaccines against severe acute respiratory syndrome. <i>Drugs of Today</i> , 2008 , 44, 63-73	2.5 21
7	Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 359, 174-9	3.4 96
6	Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. <i>Vaccine</i> , 2007 , 25, 2832-8	4.1 128
5	Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. <i>Virology</i> , 2006 , 353, 6-16	3.6 38
4	Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. <i>Vaccine</i> , 2006 , 24, 5498-508	4.1 46
3	Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus. <i>Antiviral Therapy</i> , 2005 , 10, 393-403	1.6 33
2	An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies	1
1	Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion	4